NasdaqCM - Nasdaq Real Time Price USD
GT Biopharma, Inc. (GTBP)
As of 3:31 PM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
13,287.0000
13,576.0000
21,257.0000
57,515.0000
6,764.0000
Operating Income
-13,287.0000
-13,576.0000
-21,257.0000
-57,515.0000
-6,764.0000
Net Non Operating Interest Income Expense
643.0000
567.0000
284.0000
-680.0000
-3,320.0000
Other Income Expense
1,290.0000
5,412.0000
89.0000
182.0000
-18,212.0000
Pretax Income
-11,354.0000
-7,597.0000
-20,884.0000
-58,013.0000
-28,296.0000
Net Income Common Stockholders
-11,354.0000
-7,597.0000
-20,884.0000
-58,013.0000
-28,296.0000
Diluted NI Available to Com Stockholders
-11,354.0000
-7,597.0000
-20,884.0000
-58,013.0000
-28,296.0000
Basic EPS
-7.76
-5.58
-19.46
-61.80
-193.50
Diluted EPS
-7.76
-5.58
-19.46
-61.80
-193.50
Basic Average Shares
1,473.9380
1,361.3260
1,072.9960
938.5200
146.1740
Diluted Average Shares
1,473.9380
1,361.3260
1,072.9960
938.5200
146.1740
Total Operating Income as Reported
-13,287.0000
-13,576.0000
-21,257.0000
-57,515.0000
-6,764.0000
Total Expenses
13,287.0000
13,576.0000
21,257.0000
57,515.0000
6,764.0000
Net Income from Continuing & Discontinued Operation
-11,354.0000
-7,597.0000
-20,884.0000
-58,013.0000
-28,296.0000
Normalized Income
-12,624.0000
-12,989.0000
-20,973.0000
-58,195.0000
-22,682.0000
Interest Income
643.0000
780.0000
292.0000
38.0000
--
Interest Expense
--
213.0000
8.0000
718.0000
3,320.0000
Net Interest Income
643.0000
567.0000
284.0000
-680.0000
-3,320.0000
EBIT
-11,354.0000
-7,384.0000
-20,876.0000
-57,295.0000
-24,976.0000
EBITDA
-11,354.0000
-7,384.0000
-20,876.0000
-57,295.0000
-24,976.0000
Reconciled Depreciation
12.0000
--
--
--
--
Net Income from Continuing Operation Net Minority Interest
-11,354.0000
-7,597.0000
-20,884.0000
-58,013.0000
-28,296.0000
Total Unusual Items Excluding Goodwill
1,270.0000
5,392.0000
89.0000
182.0000
-5,614.0000
Total Unusual Items
1,270.0000
5,392.0000
89.0000
182.0000
-5,614.0000
Normalized EBITDA
-12,624.0000
-12,776.0000
-20,965.0000
-57,477.0000
-19,362.0000
12/31/2020 - 3/27/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BRTX BioRestorative Therapies, Inc.
1.5800
-4.24%
BCDA BioCardia, Inc.
2.3700
-1.25%
ELTX Elicio Therapeutics, Inc.
4.6750
-1.79%
AZTR Azitra, Inc.
0.4900
-0.83%
PTIX Protagenic Therapeutics, Inc.
0.6090
-0.98%
ERAS Erasca, Inc.
3.1650
-0.47%
CNTX Context Therapeutics Inc.
2.0873
-5.98%
FRES Fresh2 Group Limited
1.3600
-2.82%
CTMX CytomX Therapeutics, Inc.
1.0000
0.00%
SCNI Scinai Immunotherapeutics Ltd.
3.5900
+2.57%